Completed OBSERVATIONAL NCT00189449

Effects of Long-Term Treatment With Nasally Inhaled Triamcinolone Acetonide in Children With Allergic Rhinitis

Sponsor: Aventis Pharmaceuticals

Conditions Allergic Rhinitis Allergy Growth

Updated 6 times since 2017 Last updated: Apr 30, 2008 Completion: Jun 30, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00189449, this observational or N/A phase trial focuses on Allergic Rhinitis and Allergy and remains completed. Sponsored by Aventis Pharmaceuticals, it has been updated 6 times since 2026, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Aventis Pharmaceuticals
West Penn Allegheny Health System

Data source: West Penn Allegheny Health System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Pittsburgh, United States